CLINICAL_TRIALS
trial_result
· 2025-05-23
Clinical Trial Update: Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF [Phase 2]
Summary
Phase 2 trial evaluating safety, efficacy, and pharmacokinetics of C21 in idiopathic pulmonary fibrosis has completed and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vicore Pharma AB | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2025-05-23